Paragon Capital Management Ltd Purchases New Holdings in CVS Health Co. (NYSE:CVS)

Paragon Capital Management Ltd purchased a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,261 shares of the pharmacy operator's stock, valued at approximately $289,000.

A number of other hedge funds have also recently added to or reduced their stakes in CVS. LaFleur & Godfrey LLC grew its stake in CVS Health by 49.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock worth $217,000 after buying an additional 1,610 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in CVS Health during the 4th quarter worth approximately $28,000. Legato Capital Management LLC lifted its position in CVS Health by 9.7% during the 4th quarter. Legato Capital Management LLC now owns 27,914 shares of the pharmacy operator's stock worth $1,253,000 after acquiring an additional 2,470 shares during the period. Van ECK Associates Corp lifted its position in CVS Health by 24.8% during the 4th quarter. Van ECK Associates Corp now owns 644,326 shares of the pharmacy operator's stock worth $28,924,000 after acquiring an additional 128,231 shares during the period. Finally, Stanley Laman Group Ltd. lifted its position in CVS Health by 1,366.8% during the 4th quarter. Stanley Laman Group Ltd. now owns 80,672 shares of the pharmacy operator's stock worth $3,621,000 after acquiring an additional 75,172 shares during the period. Hedge funds and other institutional investors own 80.66% of the company's stock.

Insider Buying and Selling at CVS Health

In related news, Director Guy P. Sansone bought 1,570 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was bought at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the transaction, the director now directly owns 12,007 shares of the company's stock, valued at approximately $764,845.90. This represents a 15.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.22% of the stock is owned by company insiders.

CVS Health Trading Up 1.6%

CVS Health stock traded up $1.07 during trading on Friday, hitting $67.42. The company's stock had a trading volume of 7,560,954 shares, compared to its average volume of 10,981,603. The stock has a market capitalization of $85.29 billion, a price-to-earnings ratio of 18.42, a P/E/G ratio of 0.98 and a beta of 0.56. The stock's fifty day moving average is $65.15 and its 200 day moving average is $60.15. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same period in the prior year, the firm posted $1.31 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 63.48%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CVS. Barclays set a $79.00 price objective on CVS Health and gave the stock an "overweight" rating in a research report on Monday, June 2nd. Truist Financial increased their price objective on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Argus set a $77.00 price target on CVS Health in a report on Tuesday, February 18th. Mizuho raised their price target on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, UBS Group raised their price target on CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $74.75.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.